A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Public ClinicalTrials.gov record NCT07192471. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Multicenter, Open-label, Non-randomized, Dose-escalation and Backfill Study of KK2223 in Participants With Relapsed or Refractory T-cell Non Hodgkin Lymphoma
Study identification
- NCT ID
- NCT07192471
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Kyowa Kirin, Inc.
- Industry
- Enrollment
- 72 participants
Conditions and interventions
Conditions
Interventions
- KK2223 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2026
- Primary completion
- Feb 28, 2029
- Completion
- Aug 31, 2030
- Last update posted
- Apr 19, 2026
2026 – 2030
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, Irvine Medical Center - Hematology/Oncology | Orange | California | 92868 | — |
| Stanford University School of Medicine | Stanford | California | 94305 | — |
| Beth Israel Deaconess Medical Center - Research | Boston | Massachusetts | 02215 | — |
| Washington University School of Medicine - Oncology Hospital - Public | St Louis | Missouri | 63110 | — |
| Hackensack University Medical Center - John Theurer Cancer C - Lymphoma Division | Hackensack | New Jersey | 07601-2105 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10021-6007 | — |
| The University of Texas - MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07192471, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 19, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07192471 live on ClinicalTrials.gov.